Tekmira Pharmaceuticals (TKMR) jumped 45% on Friday and more yesterday. If you are smart enough and have bought the stock, pat yourself on the back but I strongly suggest you should take the profit and run.
According to the company, the FDA loosened a hold on the Ebola treatment in the company's development pipeline that enables the potential use of TKM-Ebola in individuals infected with Ebola virus. The thing is, this is an investigational drug just started in human tests. In other words, there would at least a few years from now if everything goes well. Even if the drug can be successfully developed and approved for marketing, is there really a profitable market for it? I highly doubt. Ebola is a disease confined in Africa and we all know how big the market is. My gut feeling tells me that when the euphoria about this drug recedes in a few weeks or months, this stock will likely come back down to where it belongs to. Consider you have been warned.
No comments:
Post a Comment